English

Second Quarter Report Q2-2024

Report this content

The Company has advanced well with its planned activities

  • First patient dosed in Paediatric Safety Study 0202
  • Superior simulated pain efficacy in children with CT001
  • New member of the Board of Directors, Anders Dyhr D-Toft
  • US launch finalization and final approvals still ongoing...

Cessatech A/S (“Cessatech” or the “Company”) today releases its results for the period 1 April – 30 June 2024. The second quarter report is available as an attached document to this press release and on www.cessatech.com under Investor/Filings & Reports. 

Second quarter financial results 2024 (1 April - 30 June):

  • Net revenue was KDKK 0
  • Operating result was KDKK -5.382
  • Net result was KDKK -3.435
  • Cash at bank end of the period was KDKK 9.896
  • Earnings per share* was KDKK -0,20
  • Solidity** was 92%

*Earnings per share (DKK per share): Operating result divided by the average number of shares during the period. The total number of shares as of 30 June 2024 amounted to 17.425.094 shares, the average number of shares during the second quarter was 17.425.094
**Solidity: Total equity divided by total capital and liability

Comment from CEO, Jes Trygved:
Our main focus has still been the planning and preparation for the US launch of CT001, which is now planned for the 2nd half of 2024, as the US partners are pending a few local approvals but overall is still looks very promising and we are all eager to get started with the Early Access Program. We are also pleased to have initiated the Paediatric Safety Study 0202, which has made good progress, and which is the final clinical trial before we can prepare for regulatory submission for CT001. Again, a big effort from the Cessatech team and its collaboration partners.  

For more information about Cessatech, please contact:
Jes Trygved, CEO
Phone: +45 9387 2309
E-mail: jes.trygved@cessatech.com
www.cessatech.com

About Cessatech
Cessatech A/S is a Danish pharmaceutical company committed to developing and commercializing evidence-based and innovative medicines for children for the treatment of paediatric acute pain. Its lead asset (CT001) is an analgesic nasal spray for the treatment of acute and planned painful procedures in children. The advantages include needle-free administration, easy administration, a fast-acting therapeutic effect, and being medically approved for children. CT001 is at its pivotal stage of clinical development, and CT002 is at the early development phase.

Subscribe

Documents & Links